- BD (Becton, Dickinson and Company) and EMS previously announced a collaboration to launch a semaglutide therapy in Brazil, using BD’s Vystra Injection Pen platform designed for ease of use in treating chronic conditions such as obesity and type 2 diabetes.
- This partnership highlights how BD’s drug delivery expertise is being applied to support rising demand for injectable GLP-1 therapies in a major emerging healthcare market.
- Next, we’ll examine how BD’s role in semaglutide delivery through its Vystra pen platform could influence its broader investment narrative.
Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
Becton Dickinson Investment Narrative Recap
To own BD, you need to believe in its ability to grow recurring revenue from essential medical consumables and drug delivery while managing tariffs, China exposure, and the Biosciences/Diagnostics separation. The new semaglutide pen collaboration in Brazil supports the GLP 1 delivery catalyst but does not materially change the near term execution risk around the planned separation or ongoing recall and regulatory complexities.
Among recent announcements, the reaffirmed quarterly dividend of US$1.05 per share (US$4.20 annualized) stands out. It signals BD’s intent to return cash to shareholders even as it invests in areas like GLP 1 delivery platforms, which many investors see as a key long term growth driver alongside initiatives such as BD Excellence and expansion in emerging markets.
Yet, beneath BD’s GLP 1 opportunity, investors should be aware of how execution risk around the Biosciences/Diagnostics separation could...
Read the full narrative on Becton Dickinson (it's free!)
Becton Dickinson's narrative projects $21.1 billion revenue and $1.8 billion earnings by 2029. This requires a 1.8% yearly revenue decline and an earnings increase of about $0.2 billion from $1.6 billion today.
Uncover how Becton Dickinson's forecasts yield a $181.23 fair value, a 9% upside to its current price.
Exploring Other Perspectives
While consensus focuses on GLP 1 delivery and separation risk, the most optimistic analysts lean on BD Excellence for margin gains and see earnings reaching about US$1.8 billion by 2029, so you may want to compare how this new Brazil semaglutide partnership fits alongside those higher margin and earnings expectations.
Explore 2 other fair value estimates on Becton Dickinson - why the stock might be worth just $181.23!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Becton Dickinson research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Becton Dickinson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Becton Dickinson's overall financial health at a glance.
Seeking Other Investments?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com